Potential benefits of eicosapentaenoic acid on atherosclerotic plaques

For most of the last thirty years, the response to cardiovascular risk has had one move: lower LDL cholesterol with a statin, then wait. This review takes up the question that move leaves unanswered — what happens to the risk that remains once the statin is doing its job?

Its subject is eicosapentaenoic acid, or EPA, the purified omega-3 fatty acid. Rather than asking only whether EPA lowers a number on a lab report, Nelson and colleagues look at the artery wall itself. Drawing together preclinical animal work and human clinical trials, they ask whether EPA changes the character of atherosclerotic plaque — not just how much is there, but how dangerous it is.

The pattern they describe is consistent. EPA lowers triglycerides, quiets the inflammatory signaling that drives plaque growth, and appears to make plaque more stable — less prone to the rupture that causes most heart attacks. These are mechanisms that statins, for all their proven benefit, do not fully address. The implication is practical: EPA may be most useful precisely where statin therapy runs out of road, in the patient whose LDL is controlled but whose risk is not.

That framing cuts against a comfortable assumption — that a normal cholesterol panel on a statin means the work is done. It often isn’t. Resistance to the idea tends to come from two directions: clinicians who treat statins as a complete answer, and a long-standing skepticism toward fish oil, much of it earned by weak over-the-counter products that bear little resemblance to prescription-grade EPA.

Our caution here is about weight of evidence, not direction. This is a narrative review rather than original data, and its authors carry industry ties worth noting. Its conclusions lean on trials still maturing when it was written — most importantly REDUCE-IT. That is why we score its evidence strength as moderate while rating its clinical significance higher: the idea is important and increasingly actionable, but it should be read alongside the hard outcome trials built to test it.